DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has granted the Company's U.S. Patent Application No. 18/113,458, which covers the Company's ET-400 product candidate's proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 a ...